Depression Treatment Options Compared: Therapy, Medication, Lifestyle and Neuromodulation

Depression treatment falls into four broad groups: psychotherapy, antidepressant medication, lifestyle and light-based approaches, and, for depression that has not responded, augmentation strategies and brain stimulation or rapid-acting treatments such as ECT, TMS and esketamine. Psychotherapy and antidepressants have the deepest evidence and are the usual starting points; most other options either support them or come later.

This page maps those options side by side, with the strength of evidence for each and when each is typically used. For a stepwise way to put them together, see the site's step-by-step integrative depression plan.

Before choosing: get the diagnosis right

Treatment choices depend on what kind of depression is present. Bipolar depression, depression with psychotic features, depression driven by a medical problem, and depression tangled up with alcohol or other substances each call for different plans. Antidepressant labels ask prescribers to screen for bipolar disorder before starting treatment, because an antidepressant can trigger mania or hypomania in people at risk.

A good evaluation also looks at physical health, current medications, sleep, substance use and recent life events. NICE asks clinicians to review the diagnosis and consider other or coexisting conditions when treatment is not working. The site's guides on telling bipolar disorder from depression and lab tests a psychiatrist may order explain what this can involve.

All the options at a glance

Evidence strength here describes how well a treatment is studied for depression in general. It does not predict which option will suit a particular person.

Psychotherapy

The American Psychological Association's 2019 guideline found comparable effects across several therapy models for adults: behavioral therapy, cognitive and cognitive behavioral therapy (CBT), mindfulness-based cognitive therapy, interpersonal psychotherapy (IPT), psychodynamic therapies and supportive therapy. When therapy is combined with medication, it recommends CBT or IPT.

• CBT works on the links between thoughts, behavior and mood, and teaches skills to change them.
• Behavioral activation focuses on the link between what you do and how you feel, and helps reduce avoidance and withdrawal. NICE notes it may suit people whose depression has led to doing fewer things.
• IPT focuses on relationships, role changes, conflict and grief as they relate to mood.

The APA panel's conclusion that these models perform similarly is useful in practice. It means you can choose based on what you find credible, what is available, and how well you work with the therapist, rather than searching for a single correct method. What matters more is that the therapy is structured, has clear goals, and tracks whether your symptoms are actually changing.

For more severe depression, NICE describes individual CBT as usually 16 sessions, and individual behavioral activation as 12 to 16, with more if needed. The site's guide to choosing a therapy for depression goes deeper on fit, and medication, therapy or both compares the evidence for each approach.

Antidepressant medication

The 2018 Cipriani network meta-analysis in The Lancet pooled 522 trials with 116,477 participants and found all 21 antidepressants studied were more effective than placebo for adults with major depression. Differences between individual drugs were smaller, and the certainty of evidence ranged from moderate to very low.

The most commonly prescribed classes are SSRIs, SNRIs and bupropion, an NDRI. Older classes such as tricyclics and MAOIs carry more side effects, though for some people they remain the right choice. Antidepressants usually take four to eight weeks to work, and sleep, appetite and energy often improve before mood does.

Newer medicines work through different mechanisms. For example, Auvelity, a combination of dextromethorphan and bupropion, was first approved in 2022 and is FDA-approved for major depressive disorder in adults; like bupropion alone, it is not used in people with a seizure disorder or a current or past diagnosis of bulimia or anorexia nervosa. It carries the same boxed warning about suicidal thoughts and behaviors in children, adolescents and young adults as other antidepressants. How the newer options compare with each other and with older drugs is covered in newer antidepressants compared.

How a first medication is chosen, and why that choice depends on your symptoms and side-effect concerns, is covered in SSRI, SNRI or bupropion. The site's explainer on what antidepressants really do covers what treatment feels like and common side effects.

Antidepressants carry an FDA boxed warning about increased suicidal thoughts and behaviors in children, adolescents and young adults in short-term trials, and prescribers are asked to monitor closely when treatment starts. Never start, stop or change a medication on your own; work with your prescriber on any change.

Lifestyle, light and nutrition

Exercise

The APA guideline suggests exercise as an option when psychotherapy or medication is ineffective or unacceptable. NICE includes group exercise among first-line options for less severe depression, usually more than one session a week for 10 weeks with moderate-intensity aerobic activity. The site's guide to exercise for depression covers how to start when motivation is low.

Sleep

Insomnia and depression feed each other, and treating sleep directly is often part of a plan. The site's article on sleep and depression explains why.

Nutrition

A frequently discussed trial is SMILES (Jacka and colleagues, 2017). It enrolled 67 adults with moderate to severe depression and compared seven dietitian sessions supporting a healthier diet with a social-support control over 12 weeks. Remission occurred in 32.3% of the diet group and 8.0% of the control group. The results are encouraging but come from a single small trial, and most participants were already receiving therapy, medication or both, so the diet was an addition rather than a substitute.

Light therapy and supplements

For winter-pattern seasonal depression, light therapy has been a mainstay since the 1980s, typically a 10,000-lux light box for about 30 to 45 minutes each morning. For adults for whom psychotherapy and medication are ineffective or unacceptable, the APA guideline suggests exercise or St. John's wort, and then bright light therapy or yoga, as conditional options. It found insufficient evidence to recommend omega-3 fatty acids, and reported no difference in effect between St. John's wort and second-generation antidepressants in the studies it reviewed. St. John's wort can interact with serotonin-acting medications and cause serotonin syndrome, so tell your prescriber before taking it.

Special situations that change the map

Postpartum depression

Depression after childbirth is treated with the same core options, therapy and antidepressants, but it also has a medication approved specifically for it. Zuranolone (Zurzuvae), first approved in 2023, is FDA-approved for postpartum depression in adults as a once-daily oral course lasting 14 days, and can be used alone or with an oral antidepressant. It carries a boxed warning about impaired driving: patients are advised not to drive or do other potentially hazardous activities until at least 12 hours after each dose during the course. Choices during pregnancy and breastfeeding involve their own trade-offs; see postpartum depression treatment options and psychiatric medications while breastfeeding.

Teenagers

Fewer antidepressants are approved for adolescents than for adults. Fluoxetine's effectiveness for major depression has been established in children and adolescents aged 8 to 18, and escitalopram is FDA-approved for major depression in adults and in adolescents 12 and older. The boxed warning on suicidal thoughts and behaviors in young people applies here, so close monitoring early in treatment matters. Teen depression treatment, a parent's guide covers therapy options and how to involve a teenager in decisions.

Depression that may be bipolar

If there is any history of mania or hypomania, the options change, because an antidepressant can trigger mania or hypomania in people at risk. A different set of medicines has evidence here, for example the olanzapine and fluoxetine combination, which is FDA-approved for depressive episodes of bipolar I disorder. See bipolar depression treatment options.

Other common overlaps

• Winter-pattern depression: light therapy and timing matter, covered in seasonal affective disorder treatment options.
• Depression in perimenopause: hormone therapy may play a supporting role; see perimenopause depression, HRT or antidepressants.
• Depression with ADHD: the order of treatment matters; see ADHD and depression, which to treat first.

When the first treatment helps only partly

A partial response is common, and several next steps are well studied: adjusting the dose, switching medication, adding psychotherapy, or adding a second medication. In the US, aripiprazole, brexpiprazole, cariprazine and extended-release quetiapine are FDA-approved as add-on treatments to antidepressants for major depressive disorder, and a combination capsule of olanzapine and fluoxetine is FDA-approved for treatment-resistant depression. Lithium and thyroid hormone (T3) are also used as add-ons; in the US both uses are off-label, since lithium is approved for bipolar disorder and T3 for hypothyroidism.

These choices, and how a psychiatrist decides between them, are covered in what to consider when two antidepressants haven't worked.

Brain stimulation and rapid-acting treatment

Electroconvulsive therapy (ECT)

ECT has the longest history of the brain stimulation therapies for depression. It is FDA-cleared for severe depressive episodes in people 13 and older with depression or bipolar disorder, and it is given under a short-acting general anesthetic by a trained medical team. A typical course is three sessions a week, with improvement usually within 6 to 12 treatments, and follow-up medication or maintenance ECT is usually needed to keep the benefit. Memory loss, especially for the period around treatment, is a known side effect; it usually improves in the days and weeks after a course ends and is less common with unilateral ECT than with the older bilateral form. NICE suggests considering it for severe depression when a rapid response is needed, when other treatments have not worked, or when a person prefers it based on past experience.

Transcranial magnetic stimulation (TMS)

Repetitive TMS uses magnetic pulses to stimulate brain circuits without anesthesia. Its magnetic field is about the strength of an MRI scanner, and it is usually used after other treatments have been tried. The FDA cleared the first device for depression in 2008, and TMS devices are now FDA-cleared for treatment-resistant depression.

Esketamine (Spravato)

Esketamine nasal spray is FDA-approved for treatment-resistant depression in adults, either alone or with an oral antidepressant, and for depressive symptoms in adults with major depression and acute suicidal thoughts or behavior, alongside an oral antidepressant. Because of risks including sedation, dissociation and misuse, it is available only through a REMS program: it is given in certified healthcare settings under direct observation, with monitoring for at least two hours after each dose.

How the options fit together: a hypothetical path

Real treatment rarely follows a straight line, but a hypothetical example shows how the options above connect. Imagine an adult with a first episode of moderate depression, poor sleep and no history of mania.

1. The first evaluation checks for bipolar features, medical contributors, substance use and safety, and agrees on a symptom questionnaire to repeat at each visit.
2. Together they choose a starting point: weekly structured therapy, an antidepressant, or both, alongside practical steps on sleep and activity.
3. At the first review, after enough time for the treatment to work, the scores and goals show partial improvement. The prescriber adjusts the dose or the therapy focus rather than starting from scratch.
4. If improvement stalls after adequate trials, the next steps are discussed: switching medication, adding therapy if it is not already in place, or adding a second medication.
5. If two adequate antidepressant trials have not helped, the conversation widens to esketamine, TMS or ECT, weighed against severity, preferences and practical access.
6. Once well, the plan turns to staying well: how long to continue, whether relapse-prevention therapy makes sense, and what early warning signs would prompt a call.

Each step has its own detailed guide: antidepressant augmentation options compares the add-on medicines, and switching antidepressants covers what a change usually involves. Along the way, it is reasonable to ask at every review what the next step would be if the current one does not help, so a stalled plan never simply continues by default.

The point of the example is the structure, not the specific choices: a clear starting plan, a measure of progress, scheduled reviews and a defined next step at each stage.

After you feel better: preventing relapse

Recovery is a phase of treatment, not the end of it. NICE advises telling people that antidepressant treatment might need to continue for at least 6 months after symptoms remit, with regular review. For people who recovered on medication alone but are at higher risk of relapse, it suggests considering continuing the antidepressant at the dose that worked, a course of group CBT or mindfulness-based cognitive therapy (MBCT), or both. Those relapse-prevention courses usually consist of 8 sessions over 2 to 3 months, with the option of more sessions over the following year. MBCT for depression relapse explains what the course involves.

Stopping an antidepressant should be planned with the prescriber. NICE explains that it is usually necessary to reduce the dose in stages over time. Withdrawal symptoms can be mild, may appear within a few days of reducing or stopping, and usually go away within 1 to 2 weeks, but they can sometimes last longer or be severe, particularly if the medication is stopped suddenly. Switching from one antidepressant to another raises similar questions, covered in switching antidepressants, what to expect.

Tracking whether treatment is working

Feeling better is the goal, but memory for how you felt a month ago is unreliable. Short questionnaires make change visible. NICE, for example, used a PHQ-9 score of 16 as the dividing line between less severe and more severe depression when framing its recommendations, and it advises considering routine outcome monitoring with validated measures such as the PHQ-9. PHQ-9 and GAD-7 scores explained shows how to read your score and what counts as meaningful change.

Common mistakes

• Judging an antidepressant after a week or two, before it has had time to work.
• Staying on a treatment for many months without a clear review, even though little has changed.
• Changing several things at once, so nobody can tell what helped or caused a side effect.
• Stopping medication as soon as you feel well, or suddenly, without a plan with the prescriber.
• Adding supplements such as St. John's wort without telling the prescriber.
• Treating lifestyle steps as a test of willpower rather than as part of the treatment plan.

Questions to ask about any option

Whatever is proposed, a few questions help you compare it with the alternatives and decide together with your clinician:

1. What is the evidence for this treatment in someone with my type and severity of depression?
2. How long until we expect to see a change, and how will we measure it?
3. What are the common and the serious side effects, and what should I report right away?
4. What is the plan if this helps only partly, or not at all?
5. How does this fit with what I am already doing, such as therapy, other medications or supplements?
6. What will it involve in time, travel and cost, and is there a less intensive option worth trying first?

Clear answers to these questions are a sign of careful prescribing. Vague answers, or a plan that never gets reviewed, are a reason to ask for more detail or a second opinion on your medication.

When to escalate care

Move to a more intensive level of care, or contact your clinician promptly, if any of these apply:

• Thoughts of suicide, or thoughts that are becoming more frequent or more specific.
• You cannot eat, drink, work or care for yourself.
• New agitation, restlessness, sleeplessness or unusually high energy after starting or changing a medication; antidepressant labels list these among symptoms to report.
• No meaningful improvement after an adequate trial. NICE suggests a review if there has been no response after four weeks of medication at a therapeutic dose, or four to six weeks of therapy.

Signs your treatment isn't working describes how to raise this with your clinician.

If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.

Dr. Lewis's team combines psychiatric evaluation and medication management with psychotherapy, coaching, lab testing, and nutrition and lifestyle psychiatry. You can review the practice's treatment options, or see the Choosing Psychiatric Care guide for how to start.

Frequently asked questions

What is usually the first treatment for depression?

Structured psychotherapy, an antidepressant, or both. For milder depression, guided self-help or therapy is often tried first; for moderate to severe depression, many clinicians recommend combining therapy and medication.

Can lifestyle changes replace medication?

For some people with milder depression, exercise-based programs are a recognized first-line option. For moderate to severe depression, lifestyle changes generally support treatment rather than replace it. Make any medication changes only with your prescriber.

Is TMS the same as ECT?

No. ECT induces a brief controlled seizure under anesthesia. TMS uses magnetic pulses, does not require anesthesia and does not induce a seizure. They are used at different points in care.

Who can get esketamine?

Esketamine is FDA-approved for adults with treatment-resistant depression, and for adults with major depression and acute suicidal thoughts or behavior alongside an oral antidepressant. It is given only in certified healthcare settings under a REMS program.

How do I know which option is right for me?

It depends on severity, past response, other health conditions, side-effect concerns and preference. A psychiatric evaluation weighs these together, and a good clinician explains the trade-offs rather than offering one answer for everyone.

How long should I stay on an antidepressant after I feel better?

There is no single answer, and the decision belongs with your prescriber. The UK's NICE guideline says treatment might need to continue for at least 6 months after symptoms remit, with regular review, and longer for some people at higher risk of relapse.

Is there a treatment specifically for postpartum depression?

Yes. Zuranolone (Zurzuvae) is FDA-approved for postpartum depression in adults as a 14-day oral course. Therapy and standard antidepressants are also used. Talk with your clinician about which fits, including if you are breastfeeding.

Sources

1. Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts. American Psychological Association, 2019. apa.org
2. Depression in adults: treatment and management (NG222), Recommendations. National Institute for Health and Care Excellence, 2022. nice.org.uk
3. Wellbutrin XL (bupropion extended-release) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
4. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet (Cipriani et al.), 2018. pubmed.ncbi.nlm.nih.gov
5. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry (Cuijpers et al.), 2020. pubmed.ncbi.nlm.nih.gov
6. Seasonal Affective Disorder. National Institute of Mental Health, 2023. nimh.nih.gov
7. A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial). BMC Medicine (Jacka et al.), 2017. pubmed.ncbi.nlm.nih.gov
8. Abilify (aripiprazole) tablets prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
9. Spravato (esketamine) nasal spray prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
10. Brain Stimulation Therapies. National Institute of Mental Health, 2024. nimh.nih.gov
11. Mental Health Medications. National Institute of Mental Health, 2023. nimh.nih.gov
12. Rexulti (brexpiprazole) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
13. Vraylar (cariprazine) prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
14. Seroquel XR (quetiapine extended-release) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
15. Lithium carbonate prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
16. Liothyronine sodium tablets prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
17. Olanzapine and fluoxetine capsules prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
18. Zurzuvae (zuranolone) capsules prescribing information. DailyMed / U.S. FDA label (Biogen), 2026. dailymed.nlm.nih.gov
19. Prozac (fluoxetine) capsules prescribing information. DailyMed / U.S. FDA label (Eli Lilly), 2026. dailymed.nlm.nih.gov
20. Lexapro (escitalopram) prescribing information. DailyMed / U.S. FDA label (Allergan), 2026. dailymed.nlm.nih.gov
21. Auvelity (dextromethorphan and bupropion) extended-release tablets prescribing information. DailyMed / U.S. FDA label (Axsome), 2026. dailymed.nlm.nih.gov

Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.